A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid TumorsFilip Jankú, Alex A. Adjei, Jordi Rodón et al.|Cancers|2024Cited by 13